|
1
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar
|
|
2
|
Groome PA, Bolejack V, Crowley JJ, et al:
The IASLC Lung Cancer Staging Project: validation of the proposals
for revision of the T, N, and M descriptors and consequent stage
groupings in the forthcoming (seventh) edition of the TNM
classification of malignant tumours. J Thorac Oncol. 2:694–705.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ginsberg RJ and Rubinstein LV: Randomized
trial of lobectomy versus limited resection for T1 N0 non-small
cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg.
60:613–622. 1995. View Article : Google Scholar
|
|
4
|
Carr SR, Schuchert MJ, Pennathur A, et al:
Impact of tumor size on outcomes after anatomic lung resection for
stage 1A non-small cell lung cancer based on the current staging
system. J Thorac Cardiovasc Surg. 143:390–397. 2012. View Article : Google Scholar
|
|
5
|
Douillard JY, Rosell R, De Lena M, et al:
Adjuvant vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association [ANITA]): a
randomised controlled trial. Lancet Oncol. 7:719–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based
adjuvant chemotherapy in patients with completely resected
non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winton T, Livingston R, Johnson D, et al:
Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2012. View Article : Google Scholar
|
|
10
|
Ledford H: Cancer theory faces doubts.
Nature. 472:2732011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai JH, Donaher JL, Murphy DA, Chau S and
Yang J: Spatiotemporal regulation of epithelial-mesenchymal
transition is essential for squamous cell carcinoma metastasis.
Cancer Cell. 22:725–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar
|
|
14
|
Shintani Y, Okimura A, Sato K, et al:
Epithelial to mesenchymal transition is a determinant of
sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann
Thorac Surg. 92:1794–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haq R, Yokoyama S, Hawryluk EB, et al:
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that
confers resistance to BRAF inhibition. Proc Natl Acad Sci USA.
110:4321–4326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomson S, Buck E, Petti F, et al:
Epithelial to mesenchymal transition is a determinant of
sensitivity of non-small-cell lung carcinoma cell lines and
xenografts to epidermal growth factor receptor inhibition. Cancer
Res. 65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato S, Hayakawa Y, Sakurai H, Saiki I and
Yokoyama S: Mesenchymal-transitioned cancer cells instigate the
invasion of epithelial cancer cells through secretion of WNT3 and
WNT5B. Cancer Sci. 105:281–289. 2014. View Article : Google Scholar
|
|
18
|
Kin R, Kato S, Kaneto N, et al:
Procyanidin C1 from Cinnamomi Cortex inhibits TGF-β-induced
epithelial-to-mesenchymal transition in the A549 lung cancer cell
line. Int J Oncol. 43:1901–1906. 2013.PubMed/NCBI
|
|
19
|
Li J, Viallet J and Haura EB: A small
molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis
and enhances cisplatin-induced apoptosis in non-small cell lung
cancer cells. Cancer Chemother Pharmacol. 61:525–534. 2008.
View Article : Google Scholar
|
|
20
|
Henson ES, Gibson EM, Villanueva J,
Bristow NA, Haney N and Gibson SB: Increased expression of Mcl-1 is
responsible for the blockage of TRAIL-induced apoptosis mediated by
EGF/ErbB1 signaling pathway. J Cell Biochem. 89:1177–1192. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Zhang T, Wu B, Huang J, Zhou Y and
Zhu J: Chronic exposure to exogenous matrilysin induces
chemoresistance and enhances Bcl-2 expression in A549 lung
adenocarcinoma cells. Mol Biol Rep. 36:2099–2109. 2009. View Article : Google Scholar
|
|
22
|
Nishioka T, Luo LY, Shen L, et al:
Nicotine increases the resistance of lung cancer cells to cisplatin
through enhancing Bcl-2 stability. Br J Cancer. 110:1785–1792.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leu CM, Chang C and Hu C: Epidermal growth
factor (EGF) suppresses staurosporine-induced apoptosis by inducing
mcl-1 via the mitogen-activated protein kinase pathway. Oncogene.
19:1665–1675. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu Z, Ghosh S, Wang Z and Hunter T:
Downregulation of caveolin-1 function by EGF leads to the loss of
E-cadherin, increased transcriptional activity of beta-catenin, and
enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003.
View Article : Google Scholar
|
|
25
|
Hu P, Chu GC, Zhu G, et al: Multiplexed
quantum dot labeling of activated c-Met signaling in
castration-resistant human prostate cancer. PLoS One. 6:e286702011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schulze-Bergkamen H, Brenner D, Krueger A,
et al: Hepatocyte growth factor induces Mcl-1 in primary human
hepatocytes and inhibits CD95-mediated apoptosis via Akt.
Hepatology. 39:645–654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin HO, Hong SE, Woo SH, et al: Silencing
of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated
mTOR inhibition. Cell Death Dis. 3:e3192012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanchez-Tillo E, Fanlo L, Siles L, et al:
The EMT activator ZEB1 promotes tumor growth and determines
differential response to chemotherapy in mantle cell lymphoma. Cell
Death Differ. 21:247–257. 2014. View Article : Google Scholar :
|
|
29
|
Li Z, Zhao J, Du Y, et al: Downregulation
of 14-3-3zeta suppresses anchorage-independent growth of lung
cancer cells through anoikis activation. Proc Natl Acad Sci USA.
105:162–167. 2008. View Article : Google Scholar
|
